XML 16 R8.htm IDEA: XBRL DOCUMENT

Liquidity and Management's Plans	9 Months Ended
Sep. 30, 2019
Liquidity and Managements Plans [Abstract]
Liquidity and Management's Plans	Note 2 — Liquidity and Management's Plans As of September 30, 2019, the Company had cash and cash equivalents of approximately $10,551,000 and a working capital surplus of approximately $8,383,000. The Company has not generated revenues since inception and has incurred recurring operating losses. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to pursue its product development. The Company expects to further increase its research and development activities, which will increase the amount of cash utilized subsequent to September 30, 2019. Specifically, the Company expects increased spending on research and development activities and higher payroll expenses as it increases its professional and scientific staff and continues to prepare for anticipated manufacturing activities. The Company currently believes its existing cash and cash equivalents, together with the net cash proceeds received from the closing of its IPO in October 2019 and the exercise of the underwriter's option to purchase additional shares in November 2019 aggregating approximately $22,350,000 (see Note 10), will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these financial statements.

Liquidity and Management's Plans

9 Months Ended

Sep. 30, 2019

Liquidity and Managements Plans [Abstract]

Note 2 — Liquidity and Management's Plans

As of September 30, 2019, the Company had cash and cash equivalents of approximately $10,551,000 and a working capital surplus of approximately $8,383,000. The Company has not generated revenues since inception and has incurred recurring operating losses. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to pursue its product development.

The Company expects to further increase its research and development activities, which will increase the amount of cash utilized subsequent to September 30, 2019. Specifically, the Company expects increased spending on research and development activities and higher payroll expenses as it increases its professional and scientific staff and continues to prepare for anticipated manufacturing activities. The Company currently believes its existing cash and cash equivalents, together with the net cash proceeds received from the closing of its IPO in October 2019 and the exercise of the underwriter's option to purchase additional shares in November 2019 aggregating approximately $22,350,000 (see Note 10), will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these financial statements.